Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aeterna Zentaris Inc T.AEZS

Alternate Symbol(s):  AEZS

Healthcare Biotechnology
Aeterna Zentaris Inc. is a Canada-based specialty biopharmaceutical company. The Company is developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. The Company's lead product, macimorelin (Macrilen, Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The... see more

Recent & Breaking News (TSX:AEZS)

Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results

Business Wire March 29, 2016

Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2015 Financial and Operating Results on March 29, 2016

Business Wire March 15, 2016

Aeterna Zentaris Reports on Zoptrex(TM) Development Progress in China

Business Wire March 1, 2016

Company Profile for Aeterna Zentaris Inc.

Business Wire February 26, 2016

Aeterna Zentaris Commences Promotional Activities for APIFINY® Prostate Cancer Blood Test

Business Wire February 23, 2016

Aeterna Zentaris Appoints Geneviève Lemaire as Vice President, Finance and Chief Accounting Officer

Business Wire February 18, 2016

Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor Conference Seeking Partnering Opportunities

Business Wire February 1, 2016

Aeterna Zentaris Announces Appointments to Board of Directors

Business Wire January 29, 2016

Aeterna Zentaris Files International Patent Application for Novel Method of Manufacturing Zoptrex(TM)

Business Wire January 26, 2016

Aeterna Zentaris Announces Additional Market Purchases of Common Shares by Executive Management

Business Wire January 25, 2016

Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen(TM)

Business Wire January 19, 2016

Aeterna Zentaris Affirms Focus on Targeted Oncology During 2016 J.P. Morgan Healthcare Conference

Business Wire January 13, 2016

Aeterna Zentaris Announces Filing of Preliminary Base Shelf Prospectus

Business Wire December 30, 2015

Equities Lead Investor Sentiment -- Free Research on AEterna Zentaris, AMAG Pharmaceuticals, Performant Financial and Glu Mobile

Accesswire December 22, 2015

Aeterna Zentaris Announces Closing of US$16.65 Million Public Offering of Common Shares and Warrants

Business Wire December 14, 2015

Aeterna Zentaris Announces Pricing of US$16.65 Million Public Offering of Common Shares and Warrants

Business Wire December 9, 2015

Aeterna Zentaris Announces Proposed Public Offering of Common Shares and Warrants

Business Wire December 8, 2015

Aeterna Zentaris Regains Compliance with NASDAQ $1.00 Minimum Bid Price Rule and Announces 2016 Corporate Objectives

Business Wire December 8, 2015

Aeterna Zentaris and Armune BioScience Finalize Co-Marketing Agreement for APIFINY® Prostate Cancer Blood Test

Business Wire December 1, 2015

Aeterna Zentaris Affirms Fundamental Strength of Business

Canada NewsWire November 25, 2015